COMMUNIQUÉS West-GlobeNewswire

Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® PDT in Superficial Basal Cell Carcinoma
11/02/2026
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026 If approved, Ameluz ® would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal Cell Carcinoma [...]
HNL Lab Medicine Opens New Patient Service Center at The Marketplace at Steamtown
11/02/2026
SCRANTON, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine is expanding access to convenient, high-quality laboratory services with the opening of a new Patient Service Center at The Marketplace at Steamtown, [...]
Psyence BioMed Announces Settlement of Shareholder Litigation
11/02/2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (" Psyence BioMed " or the " Company ") today announced that it has entered into a settlement agreement to resolve a direct shareholder [...]
MBX Biosciences to Participate in Upcoming Investor Conferences
11/02/2026
CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide [...]
Wesley Pharmaceuticals Launches NAD+, Introducing a Signature Longevity and Skin Health Formulation to Its Product Lineup
11/02/2026
The premier 503B facility streamlines clinical access to its flagship NAD+ injection, offering an innovative wellness solution for Wesley’s nationwide client base ORLANDO, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Wesley [...]
Clairity Founder and CEO, Dr. Connie Lehman, Named to TIME’s 2026 TIME100 Health List
11/02/2026
A Global Leader in Breast Imaging and AI, Dr. Lehman is Advancing AI-Driven Risk Assessment to Identify Women at Elevated Risk Years Before Diagnosis TIME’s Annual List Recognizes 100 of the World’s Most Influential [...]
Laseroptek America Files Counterclaims Alleging Anticompetitive and Unfair Business Practices in Ongoing Litigation with Strata Skin Sciences
11/02/2026
LAGUNA HILLS, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Laseroptek America Corp. (“Laseroptek America” or “LOA”) today announced that it has filed counterclaims and third-party claims against Strata Skin Sciences, Inc [...]
Helus Pharma nomme Michael Cola au poste de directeur général pour piloter la prochaine phase de développement et d’exécution
11/02/2026
Ancien président de la division pharmaceutique spécialisée de Shire PLC (« Shire »), il cumule plus de 30 ans d’expérience dans les domaines des neurosciences, des maladies rares et des produits pharmaceutiques [...]
CalMHSA Selects Eleos as Statewide AI Technology Partner for Behavioral Health
11/02/2026
Eleos’ AI platform pairs with Streamline Healthcare Solutions’ EHR in counties across California, supporting enhanced human connection in behavioral health care delivery BOSTON and OAK BROOK, Ill. and SACRAMENTO, Calif [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026
DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces expanded leadership roles [...]
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]

Pages